SBIR/STTR Research Award

Nanomaterials for Retinal Detachment Repair

Award identifier 86fef2c3bbdcfaaa4120c155c4deb74a9fb6c0071c317fdabea437763dcae645Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$105,000

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Nanomedics, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Nanomaterials for Retinal Detachment Repair Retinal Detachment is a leading cause of blindness, and currently available treatments fail in as many as 1/3 of patients, resulting in partial or complete loss of vision for several million people worldwide. The fundamental principal of retinal detachment repair is closure of the retinal break(s), or tamponade. Current means of tamponade are inadequate for closing retinal holes in all patients. Present internal tamponades such as polydimethylsiloxane fluid or halogenated gases depend on density and float up. They cannot adequately treat inferior retinal holes, leaving large portions of the retina untreated. The ultimate goal is to develop a 360x stable tamponade for treating retina detachment. The heart of the proposed system will be a magnetic polydimethylsiloxane-nanoparticle fluid to be placed into the vitreous cavity by intravitreal injection in a similar manner to that presently utilized for non-magnetic silicone tamponades. It will be securely held in place at a retina break by an external permanent magnet band. The central vitreous cavity (and visual axis) will be free of the magnetic fluid, and there will be no contact between the magnetic fluid and the lens, anterior chamber structures, or macula, thus avoiding the complications of currently available treatment modalities. The objective of this Phase I proposal is to (1) establish that the new magnetic silicone fluid is non-toxic to ocular structures, and (2) to establish feasibility regarding whether the new magnetic system has sufficient magnetophoretic mobility to effectively hold the retina in place.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.